ERBB2 and breast carcinoma: However, ICIs, DDRi, and anti-HER2+ mAbs therapies affect one or a few pathological molecular pathways, likely without a significant impact on the immunosuppressive TME, while the ER-mediated anti-estrogen action in ER+ breast cancer involves multiple genes and several pathological pathways [157,185,186] favoring the reversion of the immunosuppressive TME.